Carter Cliff

Carter Cliff has an extensive work experience in the biotechnology and healthcare industry. Carter is currently serving as the Acting CEO at Papillon Therapeutics Inc, a position they took on in February 2023. Prior to this, they co-founded and served as the Director at Ryne Biotechnology since January 2023. In 2017, they co-founded Vascugen and held the role of Director. Carter also co-founded Opsis Therapeutics in 2016. Additionally, they co-founded and was a Director at RPRD Diagnostics from October 2016. Carter served as a Venture Partner at Saisei Ventures starting from June 2021. In 2016, they founded and was the Principal at D1ASP0RA. Carter Cliff was also a Co-founder and Director at Dianomi Therapeutics from March 2017 to 2020. Prior to their entrepreneurial ventures, they worked as the Director of Business Development at Cellular Dynamics International from June 2010 to March 2016. Carter started their career in the industry in 2005 as a Sales representative at Meso Scale Discovery, where they worked until June 2010.

Carter Cliff began their education in 1994 at the New Mexico Institute of Mining and Technology, where they pursued a Dual B.S. degree in Chemistry & Biology. Carter successfully completed this program in 1998. After that, they attended The University of Texas at Austin from 1998 to 1999 for further studies in Molecular Biology. Then, from 1999 to 2001, Cliff attended UT Southwestern Medical Center, focusing on Cell & Molecular Biology. No degree is listed for this period.